Recently, a novel PAI-1 inhibitor, ACT001, currently in phase I clinical trials for glioblastoma treatment, attenuated phosphorylation of PI3K and its downstream target AKT, inhibiting U118MG proliferation, migration, invasion and metastasis while triggering a pro-apoptotic response [213,214]. This evidence concerns the gene AKT1 and glioblastoma.